The success of cell and gene therapy products in recent years to treat a host of complex diseases has made production that much more critical. Many companies have begun to ramp up production timelines, so as to meet patients’ needs, while still producing efficacious and safe cell and gene therapy materials. However, many biomanufacturers have found themselves in a bit of a quandary: How do we traverse the turbulent regulatory waters governing the production of these novel products? Moreover, how has the COVID-19 pandemic affected the regulatory process? Thankfully, the experienced team at MilliporeSigma has surveyed the landscape and can offer some insight into these critical issues. In this GENcast, we chatted with two team members and picked their brains about some of the challenges currently facing manufacturers in this space. Listen in and hear what they have to say…
Jessica Hoganhttps://emergingbiotalk.com/author/jessica-hogan/April 19, 2023
Jessica Hoganhttps://emergingbiotalk.com/author/jessica-hogan/April 12, 2023
Jessica Hoganhttps://emergingbiotalk.com/author/jessica-hogan/April 5, 2023
Watch on Demand! The Current State of Emerging Biotech Venture Capital & How to Successfully Raise Funds
Insights on the changes in the biotech VC landscape and tips from an investor perspective for companies fundraising...
by Bauke Anninga November 2, 2023
Collaboration between biomanufacturers and CDMOs often experiences challenges with data sharing. This presentation highlights the management of heterogenous...
by Olga Shabelnikova and Braj Nandan Thakur October 26, 2023
The definition of Good Laboratory Practice (GLP) is given by the Organization for Economic Co-operation and Development (OECD)…
by Lynn Neild October 18, 2023
Understanding regulatory expectations for ancillary/raw materials during development and early clinical phases can be challenging. Join in for...